



# SYNCOM FORMULATIONS (INDIA) LTD.

Regd. Off.: 7, Niraj Industrial Estate, Off Mahakali Caves Road, Andheri (E), MUMBAI -400 093

Works : 256-257, Sector. 1, Pithampur (Dhar), E-mail : info@sfil.in, www.sfil.in

CIN : L24239MH1988PLC047759

## UNAUDITED STANDALONE FINANCIAL RESULTS FOR THE QUARTER ENDED 30<sup>th</sup> JUNE, 2017

Sr. No.	PARTICULARS	Quarter Ended		₹ IN LACS
		10.06.2011	10.06.2016	Year Ended
		(Unaudited)	(Unaudited)	(Audited)
1	Income from Operations			
	(a) Net sales (net of excise duty)	4102.53	4349.38	18275.09
2	Other Income	70.99	85.12	486.24
3	Total Income	<b>4173.52</b>	<b>4434.50</b>	<b>18761.33</b>
4	Expenses			
	(a) Cost of Material Consumed	2067.91	1660.95	6902.10
	(b) Purchase of stock in trade	1210.85	848.04	5412.19
	(c) Changes in inventories of finished goods, Work in progress and stock in trade	(408.75)	482.73	496.71
	(d) Employee Benefit Expenses	363.85	360.45	1491.68
	(e) Finance Cost	5.24	6.90	28.18
	(f) Depreciation and amortization Expenses	90.69	85.00	312.28
	(g) Other Expenses	529.02	612.44	2559.54
	Total Expenses (4)	<b>3858.81</b>	<b>4056.51</b>	<b>17172.68</b>
5	Profit/(loss) before exceptional & extraordinary item and tax (3-4)	<b>314.71</b>	<b>377.99</b>	<b>1588.65</b>
6	Exceptional Items	0.00	0.00	0.00
7	Profit/(loss) before extraordinary items & tax (5-6)	314.71	377.99	1588.65
8	Extraordinary Items	0.00	0.00	0.90
9	Profit before tax (7-8)	314.71	377.99	1587.75
10	Tax Expenses			
	(a) Current Tax	104.00	115.10	403.26
	(b) Deferred Tax	8.25	9.90	131.08
11	Profit/(loss) for the period from continuing operations (9-10)	<b>202.46</b>	<b>252.99</b>	<b>1053.41</b>
12	Profit/(loss) from discontinuing operations	0.00	0.00	0.00
13	Tax Expenses of discontinuing Operations (after Tax)	0.00	0.00	0.00
14	Profit/(loss) for the period from Discontinuing operations (after Tax) (12-13)	0.00	0.00	0.00
15	Profit/(loss) for the period (11+14)	<b>202.46</b>	<b>252.99</b>	<b>1053.41</b>
16	Other Comprehensive Income :			
A	(i) Items that will not be reclassified to P&L	(2.37)	11.13	(29.11)
	(ii) Income Tax relating to items that will not be reclassified to Profit & Loss	0.00	0.00	0.00
B	(i) Items that will be reclassified to P&L	0.00	0.00	0.00
	(ii) Income tax relating to items that will be reclassified to Profit & Loss	0.00	0.00	0.00
17	Total comprehensive income for the period (16+17) (Comprising Profit/(loss) and other comprehensive income for the period	200.09	264.12	1024.30
18	Earning Per Share (of Rs. 1/- each) for continuing Operations			
	(a) Basic	0.03	0.03	0.13
	(b) Diluted	0.03	0.03	0.13
19	Earning Per Share (of Rs. 1/- each) for Dis-continuing Operations			
	(a) Basic	0.00	0.00	0.00
	(b) Diluted	0.00	0.00	0.00
20	Earning Per Share (of Rs. 1/- each) for Dis-continuing Operations and continuing operations			
	(a) Basic	0.03	0.03	0.13
	(b) Diluted	0.03	0.03	0.13

### Notes :

- The above results were reviewed by the Audit Committee and then approved by the Board at their respective meetings held on 14.08.2017. The statutory auditors of the Company have carried out limited review of the Unaudited Financial Results for the quarter ended 30.06.2017.
- The Company has adopted Indian Accounting Standard ("Ind AS") from 01.04.2017 and accordingly these financial results have been prepared in accordance with the recognition and measurement principles laid down in the Ind AS 34 Interim Financial reporting prescribed under Section 133 of the Companies Act, 2013 read with the relevant rules issued thereunder

## STATEMENT OF SEGMENT WISE REVENUE, RESULTS AND CAPITAL EMPLOYED

Sr. No.	PARTICULARS	Quarter Ended		Year Ended
		30.06.2017	30.06.2016	31.01.2011
		(Unaudited)	(Unaudited)	(Audited)
		(Rs. in lacs)		
1	<b>Segment Revenue</b>			
	(a) Pharmaceuticals Drugs & Formulations	3090.16	4011.91	15423.76
	(b) Trading of Commodities	1030.10	356.01	3127.10
	(c) Renting of Property	53.26	66.58	210.46
	<b>Total</b>	<b>4173.52</b>	<b>4434.50</b>	<b>18761.32</b>
	<b>Less: Inter Segment Revenue</b>	0.00	0.00	0.00
	<b>Net Sales/Income from Operations</b>	<b>4174.00</b>	<b>4434.50</b>	<b>18761.32</b>
2	<b>Segment Results (Profit)+/Loss(-) before tax and interest from each Segment</b>			
	(a) Pharmaceuticals Drugs & Formulations	190.53	312.97	1162.89
	(b) Trading of Commodities	76.16	5.35	243.47
	(c) Renting of Property	53.26	66.58	210.46
	<b>Total</b>	<b>319.95</b>	<b>384.90</b>	<b>1616.82</b>
	<b>Less: (i) Interest</b>	5.24	6.90	28.18
	<b>(ii) Other Un-allocable Expenditure (net off Un-allocable Income)</b>	0.00	0.00	0.90
	<b>Total Profit Before Tax</b>	<b>314.71</b>	<b>378.00</b>	<b>1587.74</b>
3	<b>Segment Assets</b>			
	(a) Pharmaceuticals Drugs & Formulations	14768.16	12083.33	13833.43
	(b) Trading of Commodities	510.43	330.41	314.44
	(c) Renting of Property	2987.19	3907.12	3868.41
	(d) Unallocated	0.00	0.00	0.00
	<b>Total Assets</b>	<b>18265.78</b>	<b>16320.86</b>	<b>18016.68</b>
4	<b>Segment Liabilities</b>			
	(a) Pharmaceuticals Drugs & Formulations	6169.46	5027.32	6064.02
	(b) Trading of Commodities	42.19	0.45	160.56
	(c) Renting of Property	116.22	170.12	56.64
	(d) Unallocated	0.00	0.00	0.00
	<b>Total Liabilities</b>	<b>6327.87</b>	<b>5197.89</b>	<b>6281.22</b>

3 The financial results for the quarter ended 30.06.2016 have not been reviewed by the Statutory auditors. However, the management has exercised necessary due diligence to ensure that the financial results provide a true and fair view of the Company's affairs.

4. Reconciliation of Net profit as previously reported on account of transition from the previous Indian GAAP to Ind AS for the quarter ended 30.06.2016.

Particulars	Quarter Ended 30.06.2016 (Unaudited)
Net profit for the quarter under Previous Indian GAAP	252.99
Profit on valuation of financial instruments through Profit and Loss A/c	0.00
Net profit for the quarter under Ind AS	252.99
Other Comprehensive Income/(expenses) (net of tax)	11.13
Total Comprehensive income for the quarter	264.12

5 The Company is operating in three segments i.e. (a) Pharmaceuticals Drugs & Formulations (b) Trading of commodities and (c) Renting of property, particulars for segment wise results are as above.

6. Company has closed its 100% Wholly Owned Foreign Subsidiary namely Trade Services FZE on 25th April, 2017.

7. Previous quarter's figures have been regrouped/reclassified where necessary.

Place : Indore  
Dated : 14/08/2017

By  of the Board of Directors  
For Syncom Formulations (India) Ltd.  
K. S. MAL BANKDA  
Chairman & Wholtime Director  
DIN 00827050